Canakinumab + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Coronavirus Infection

Conditions

Coronavirus Infection, Diabetes Mellitus, Type 2

Trial Timeline

Oct 23, 2020 → Aug 17, 2021

NCT ID

NCT04510493

About Canakinumab + Placebo

Canakinumab + Placebo is a phase 3 stage product being developed by Novartis for Coronavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04510493. Target conditions include Coronavirus Infection, Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05725343	Phase 3	Terminated	Feb 3, 2022	Sep 21, 2022	Lung Cancer
NCT04510493	Phase 3	Completed	Oct 23, 2020	Aug 17, 2021	Coronavirus Infection
NCT04362813	Phase 3	Completed	Apr 30, 2020	Dec 22, 2020	Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
NCT03447769	Phase 3	Terminated	Mar 16, 2018	Feb 7, 2023	Non-Small Cell Lung Cancer
NCT02059291	Phase 3	Completed	Jun 27, 2014	Jul 4, 2017	Hereditary Periodic Fevers
NCT01390350	Phase 2	Completed	Jul 1, 2011	May 1, 2018	Schnitzler Syndrome
NCT00889863	Phase 3	Completed	Jul 1, 2009	Sep 1, 2011	Systemic Juvenile Idiopathic Arthritis With Active Flare
NCT00886769	Phase 3	Terminated	Jul 1, 2009	Jan 1, 2011	Systemic Juvenile Idiopathic Arthritis
NCT00581945	Phase 1/2	Completed	Jan 1, 2007	May 1, 2010	Chronic Obstructive Pulmonary Disease
NCT00424346	Phase 2	Completed	Nov 1, 2006	Oct 1, 2009	Rheumatoid Arthritis

Competing Products

20 competing products in Coronavirus Infection

See all competitors

Product	Company	Stage	Hype Score
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	77
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mg	Eli Lilly	Phase 2/3	65
EQ001 + EQ001 Placebo	Biocon	Phase 3	77
Mesenchymal stem cell	Rohto Pharmaceutical	Phase 1	33
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04	AbbVie	Phase 1	33
Ibrutinib + Placebo	AbbVie	Phase 2	52
600 mg AZD7442 IV + 600mg placebo IV	AstraZeneca	Phase 2	52
EVUSHELD	AstraZeneca	Pre-clinical	23
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])	AstraZeneca	Phase 2	52
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IV	AstraZeneca	Phase 1	33
Molnupiravir + Placebo	Merck	Phase 3	77
Molnupiravir + Placebo	Merck	Phase 2/3	65
V590	Merck	Phase 1	33
Molnupiravir + Placebo	Merck	Phase 2/3	65
V591	Merck	Phase 1/2	41
Efprezimod alfa + Placebo	Merck	Phase 3	77
M5049 + M5049 + Placebo	Merck	Phase 2	52
Molnupiravir + Placebo	Merck	Phase 3	77
Frespaciguat + Placebo	Merck	Phase 1	33
Ruxolitinib + Fostamatinib	Novartis	Phase 1/2	41

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved